LantheusLNTH
About: Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Employees: 834
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
67% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 10 (+4) [Q3]
60% more call options, than puts
Call options by funds: $93.8M | Put options by funds: $58.8M
46% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 69
38% more capital invested
Capital invested by funds: $5.54B [Q2] → $7.62B (+$2.09B) [Q3]
7% more funds holding
Funds holding: 449 [Q2] → 481 (+32) [Q3]
0.89% more ownership
Funds ownership: 99.56% [Q2] → 100.45% (+0.89%) [Q3]
8% less repeat investments, than reductions
Existing positions increased: 159 | Existing positions reduced: 172
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Truist Securities Richard Newitter 66% 1-year accuracy 31 / 47 met price target | 56%upside $120 | Buy Reiterated | 8 Nov 2024 |
JMP Securities David Turkaly 28% 1-year accuracy 7 / 25 met price target | 46%upside $112 | Market Outperform Maintained | 7 Nov 2024 |
Redburn Atlantic Ed Ridley-Day 100% 1-year accuracy 1 / 1 met price target | 128%upside $175 | Buy Initiated | 3 Sept 2024 |
Financial journalist opinion
Based on 6 articles about LNTH published over the past 30 days
